The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant ...

NEW YORK, NY AND RABAT, MOROCCO / ACCESS Newswire / June 20, 2025 / DeepEcho, an AI first healthtech company revolutionizing maternal and fetal health, has received clearance from the U.S. Food and Dr ...

From a price-performance perspective, PFE has performed better than BMY so far this year. Shares of PFE have declined 6.8%, ...